Journal of Diagnostics Concepts & Practice >
Summary and interpretation of the World Health Organization “Global Report on Hypertension”
Received date: 2024-04-15
Accepted date: 2024-05-08
Online published: 2024-06-25
In 2023, the World Health Organization (WHO) released the first document of “Global report on hypertension—The race against a silent killer”. which covers the global prevalence and management of hypertension, analyzes the mortality and disease burden caused by hypertension, explores the risk factors for hypertension, evaluates the cost-effectiveness of blood pressure treatment, and presents successful examples of hypertension management in many countries, especially the global implementation of the WHO-launched HEARTS project for hypertension control. Hypertension is a significant global public health challenge with severe health implications. Over the past 30 years, the number of people with hypertension (defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or taking antihypertensive medication) has doubled, rising from 650 million in 1990 to 1.3 billion in 2019. Among the global hypertensive population aged 30-79, approximately 54% have been diagnosed, of which 42% are receiving antihypertensive treatment, and only 21% have controlled blood pressure. In 2019, elevated systolic pressure was responsible for over half of cardiovascular disease deaths globally. Increasing the global hypertension control rate to 50% could prevent 76 million deaths from 2023 to 2050. Population-level risk factors for hypertension include high salt and low potassium intake, alcohol consumption, physical inactivity, and air pollution. WHO advocates for the prevention and control of hypertension through measures such as reducing dietary sodium intake, increasing potassium intake, limiting alcohol consumption, quitting smoking, increasing physical activity, and improving air quality. In terms of treatment, WHO guidelines recommend antihypertensive medication for individuals with systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. For specific populations, it is also recommended to start antihypertensive treatment when systolic blood pressure is between 130-139 mmHg. The use of single-pill combination therapy is also advised to improve adherence and persistence in treatment. The prevalence and management of hypertension in China are also noteworthy. Hypertension is a major cause of mortality and disease burden in the Chinese population. By learning from global successes in hypertension management, China can enhance its efforts in the prevention, control, and monitoring of hypertension, particularly by promoting the application of the HEARTS technical package to improve hypertension management. This report aims to draw attention to major non-communicable diseases, particularly hypertension, as a public health challenge. Through detailed data analysis and successful case studies, the report underscores the importance of hypertension prevention and control, providing scientific evidence for policy-making across countries. This collective effort aims to achieve the global goal of a 25% relative reduction in uncontrolled hypertension prevalence by 2025 compared to 2010. This article will interpret briefly the reports based on the prevalence and management of hypertension in China.
Key words: Hypertension; Prevalence; Mortality; Disease burden
ZHANG Dongyan , LI Yan . Summary and interpretation of the World Health Organization “Global Report on Hypertension”[J]. Journal of Diagnostics Concepts & Practice, 2024 , 23(03) : 297 -304 . DOI: 10.16150/j.1671-2870.2024.03.007
[1] | NCD Risk Factor Collaboration NCD-RisC. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021, 398(10304):957-980. |
[2] | FOROUZANFAR M H, LIU P, ROTH G A, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015[J]. JAMA, 2017, 317(2):165-182. |
[3] | GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Di-sease Study 2019[J]. Lancet,2020, 396(10258):1223-1249. |
[4] | World Health Organization. Global report on hypertension: the race against a silent killer[R/OL]. [2024-04-16]. https://www.who.int/publications/i/item/9789240081062. |
[5] | Global Health Observatory GHO. Noncommunicable diseases: risk factors[R/OL]. Geneva: World Health Organization,2023-08-02[2024-04-16]. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-risk-factors. |
[6] | World Bank income groups for 2019[R/OL]. 2023-08-02[2024-04-16]. https://datatopics.worldbank.org/world-development-indicators/stories/the-classification-of-countries-by-income.html. |
[7] | ZHOU B, PEREL P, MENSAH G A, et al. Global epidemiology, health burden and effective interventions for ele-vated blood pressure and hypertension[J]. Nat Rev Cardiol, 2021, 18(11):785-802. |
[8] | 国家心血管病中心. 中国心血管健康与疾病报告2022[M]. 北京: 中国协和医科大学出版社, 2023. |
National Center for Cardiovascular Disease. China. Annual report on cardiovascular health and disease in China (2022)[M]. Beijing: Peking Union Medical College Press, 2023. | |
[9] | WANG Z, CHEN Z, ZHANG L, et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015[J]. Circulation, 2018, 137(22):2344-2356. |
[10] | WHO global report on sodium intake reduction[R/OL]. Geneva: World Health Organization, 2023[2024-04-16]. https://who.int/iris/handle/10665/366393. |
[11] | Sodium Country Score Card[R/OL]. Geneva: World Health Organization.2023-08-21[2024-04-16]. https://extranet.who.int/nutrition/gina/en/scorecard/sodium. |
[12] | NEAL B, WU Y, FENG X, et al. Effect of Salt Substitution on Cardiovascular Events and Death[J]. N Engl J Med, 2021, 385(12):1067-1077. |
[13] | XU A, MA J, GUO X, et al. Association of a Province-Wide Intervention With Salt Intake and Hypertension in Shandong Province, China, 2011-2016[J]. JAMA Intern Med, 2020, 180(6):877-886. |
[14] | The SAFER technical package: five areas of intervention at national and subnational levels[M/OL]. Geneva: World Health Organization. 2019[2024-04-16]. https://who.int/iris/handle/10665/330053. |
[15] | VIRDIS A, GIANNARELLI C, NEVES M F, et al. Cigarette smoking and hypertension[J]. Curr Pharm Des, 2010, 16(23):2518-2525. |
[16] | GBD results tool, Institute of Health Metrics[R/OL]. 2023-08-02[2024-04-16]. https://www.healthdata.org/data-tools-practices/interactive-visuals/gbd-results. |
[17] | Guideline for the pharmacological treatment of hypertension in adults[M/OL]. Geneva: World Health Organization. 2021[2024-04-16]. https://who.int/iris/handle/10665/344424. |
[18] | 2018 physical activity guidelines advisory committee scientific report[M]. Washington, DC: US Department of Health and Human Services, 2018. |
[19] | COSTA E C, HAY J L, KEHLER D S, et al. Effects of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training On Blood Pressure in Adults with Pre- to Established Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials[J]. Sports Med, 2018, 48(9):2127-2142. |
[20] | Guidelines on physical activity and sedentary behavior[M/OL]. Geneva: World Health Organization, 2020[2024-04-16]. https://who.int/iris/handle/10665/336656. |
[21] | SANTOS A C, WILLUMSEN J, MEHEUS F, et al. The cost of inaction on physical inactivity to public health-care systems: a population-attributable fraction analysis[J]. Lancet Glob Health, 2023, 11(1):e32-e39. |
[22] | ACTIVE: a technical package for increasing physical activity[M/OL]. Geneva: World Health Organization, 2019[2024-04-16]. https://who.int/iris/handle/10665/275415. |
[23] | WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dio-xide and carbon monoxide[M/OL]. Geneva: World Health Organization, 2021[2024-04-16]. https://who.int/iris/handle/10665/345329. |
[24] | IEA, IRENA, UNSD, World Bank, WHO. Tracking SDG 7: the energy progress report[M/OL]. Washington, DC: World Bank, 2023. |
[25] | Global Health Observatory GHO. Air pollution[R/OL]. Geneva: World Health Organization.2023-08-02[2024-04-16]. https://www.who.int/data/gho/data/themes/air-pollution. |
[26] | QIN P, LUO X, ZENG Y, et al. Long-term association of ambient air pollution and hypertension in adults and in children: A systematic review and meta-analysis[J]. Sci Total Environ, 2021, 796:148620. |
[27] | ZHAO M, XU Z, GUO Q, et al. Association between long-term exposure to PM2.5 and hypertension: A systematic review and meta-analysis of observational studies[J]. Environ Res, 2022, 204(Pt D):112352. |
[28] | WHO methods and data sources for country-level causes of death 2000-2019[R/OL]. Geneva: World Health Organization.2023-08-02[2024-04-16]. https://www.who.int/docs/default-source/gho-documents/global-health-estimates/ghe2019_cod_methods.pdf. |
[29] | 中国高血压防治指南修订委员会, 高血压联盟中国, 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56. |
Writing Group of 2018 Chinese Guidelines for the Mana-gement of Hypertension, Chinese Hypertension League, Chinese Society of Cardiology, et al. 2018 Chinese guidelines for the management of hypertension[J]. Chin J Cardiovasc Med, 2019, 24(1):24-56. | |
[30] | Global Hearts Initiative. Working together to beat cardiovascular diseases[R/OL]. Geneva: World Health Organization.2023-08-02[2024-04-16]. https://www.who.int/news/item/15-09-2016-global-hearts-initiative. |
[31] | Hearts: technical package for cardiovascular disease management in primary health care[M/OL]. Geneva: World Health Organization, 2016[2024-04-16]. https://who.int/iris/handle/10665/252661. |
/
〈 |
|
〉 |